Multicentral pilot clinical trial of gliatilin in treatment of acute ischemic stroke

Cover Page


Cite item

Full Text

Abstract

The multicentral pilot clinical trial of gliatilin in treatment of acute ischemic stroke was held in 2006–2008 in Russia. The trial involved 122 patients, who received basic treatment and gliatilin during 3 months after the stroke onset (1–15 days – 2000 mg per day, 16–30 days – 1000 mg per day, 31–90 days – 800 mg per day). All patients underwent clinical examination (including repeated NIHSS, Rankin scale, Barthel index assessment), laboratory and ultrasound examination, computer tomography or magnetic resonance imaging during 24 hours after the stroke onset. 25 patients underwent repeated multimodal magnetic resonance imaging (T1-, T2-, diffusion-, perfusion-weighted imaging). The results of examination of patients who received basic treatment alone were taken from literature. The trial results show, that treatment of acute ischemic stroke with gliatilin promotes neurological recovery and increase of patient’s self-care ability, which is probably concerned with the smaller final volume of brain infarct.

 

About the authors

Miroslav M. Odinak

S.M. Kirov Military Medical Academy

Email: voznjouk@yandex.ru
Russian Federation, St. Petersburg

Igor A. Voznyuk

S.M. Kirov Military Medical Academy

Author for correspondence.
Email: voznjouk@yandex.ru
ORCID iD: 0000-0002-0340-4110

D. Sci. (Med.), Professor, Department of Neurology, First Pavlov State Medical University; Professor, Department of Nervous Diseases, S.M. Kirov Military Medical Academy

Russian Federation, St. Petersburg

Mikhail A. Piradov

Research Center of Neurology

Email: voznjouk@yandex.ru
ORCID iD: 0000-0002-6338-0392

D. Sci. (Med.), Professor, Full Member of the Russian Academy of Sciences, Director

Russian Federation, Moscow

S. A. Rumyantseva

Clinical hospital № 15

Email: voznjouk@yandex.ru
Russian Federation, Moscow

A. N. Kuznetsov

National medico-surgical center of N.I. Pirogov

Email: voznjouk@yandex.ru
Russian Federation, Moscow

S. N. Yanishevskiy

Military Medical Academy

Email: voznjouk@yandex.ru
Russian Federation, Saint Petersburg

S. Yu. Golokhvastov

Military Medical Academy

Email: voznjouk@yandex.ru
Russian Federation, Saint Petersburg

N. V. Tsygan

Military Medical Academy

Email: voznjouk@yandex.ru
Russian Federation, Saint Petersburg

References

  1. Верещагин Н.В., Пирадов М.А. Принципы ведения и лечения больных в острейшем периоде инсульта. Интенсивная терапия острых нарушений мозгового кровообращения. Орел, 1997: 3–11.
  2. Виленский Б.С. Инсульт: профилактика, диагностика и лечение. СПб.: Фолиант, 2002: 397.
  3. Виленский Б.С. Современная тактика борьбы с инсультом. СПб.: Фолиант, 2005: 288.
  4. Вознюк И.А., Голохвастов С.Ю., Фокин В.А. и др. Нарушения церебрального кровотока и перфузионные расстройства в остром периоде ишемического инсульта. Инсульт (Прилож. к Журн. неврологии и психиатрии им. С.С. Корсакова) 2007. Спец. вып. 242–243.
  5. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001: 327.
  6. Инсульт: диагностика, лечение, профилактика / Под ред. З.А. Суслиной, М.А. Пирадова. М.: МЕДпресс-информ, 2008: 283.
  7. Одинак М.М., Вознюк И.А. Новое в терапии при острой и хронической патологии мозга. СПб.: ВМедА, 2000: 31.
  8. Одинак М.М., Вознюк И.А., Янишевский С.Н. Ишемия мозга (нейропротективная терапия, дифференцированный подход). СПб.: ВМедА, 2002: 75.
  9. Одинак М.М., Вознюк И.А. Ишемия мозга – преемственность в решении проблемы. Мед. акад. журн. 2006; т. 6: 3: 88–94.
  10. Одинак М.М., Вознюк И.А., Голохвастов С.Ю. и др. Мониторинг перфузионных нарушений в острейшую стадию ишемического инсульта. Вестн. Рос. воен.-мед. акад. 2005; 2: 25–30.
  11. Одинак М.М., Вознюк И.А., Голохвастов С.Ю., и др. Особенности ранней нейровизуализационной диагностики при острых нарушениях мозгового кровообращения. Регионарное кровообращение и микроциркуляция. 2007: 1: 113–114.
  12. Одинак М.М., Вознюк И.А., Янишевский С.Н. Инсульт. Вопросы этиологии, патогенеза. Алгоритмы диагностики и терапии. СПб.: ВМедА, 2005: 192.
  13. Труфанов Г.Е., Одинак М.М., Фокин В.А. Магнитно-резо- нансная томография в диагностике ишемического инсульта. СПб.: ЭЛБИ-СПб, 2008: 271.
  14. Труфанов Г.Е., Фокин В.А., И.В. Пьянов и др. Рентгеновская компьютерная и магнитно-резонансная томография в диагностике ишемического инсульта. СПб.: ЭЛБИ-СПб, 2005: 192.
  15. Barbagallo S.G., Barbagallo M., Giordano M. et al. Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Pharmacology of Aging Process (Annals of the New York Academy of Sciences). 1994; 717: 253–269.
  16. Bergamaschi M., Piccolo O. Deacylated phospholipids: Chemistry and therapeutic potential. Phospholipids: characterization, metabolism, and novel biological applications / Ed. by G. Cvec, F. Paltauf. AOCS Press, USA 1995: 228–247.
  17. Blusztajn J.K., Wurtman R.J. Choline and cholinergic neurons. Science 1983; 221: 19-22.
  18. Casamenti F., Mantovani P., Amaducci L., Pepeu G. Effect of phosphatidylserine on Ach output from the cerebral cortex of the rat. J. Neurochem 1979; 32: 529–533.
  19. Clark W.M., Wissman S., Albers G.W. et al. Recombinant Tissue- Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study. J. Am. Med. Association 1999; 282: 21: 2019–2026.
  20. D’Orlando J.K., Sandage B.W. Citicoline (CDP-choline): mechanism of action and effects in ischemic brain injury. Neurol. Res. 1995; 17: 281–284.
  21. Delwaide P.J., Gyeselynck A.M., Hurlet A., Ylieff M. Double-blind randomized controlled study of phosphatidylserine in senile patients. Acta Neurol. Scand 1986; 73: 136–140.
  22. Dorman P.J., Sandercock P.A. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Stroke 1996; 27: 9: 1507–1515.
  23. Dross K., Kevitz H. Concentration and origin of choline in the rat brain. N.S. Arch. Pharmacol. 1972; 274: 91–10.
  24. Fisher M., Takano K. The penumbra, therapeutic time window and acute ischemic stroke. Baillieres Clin. Neurol. 1995; 4: 2: 279–295.
  25. Flentge F., Van Der Berg C.J. Choline administration and Ach in brain. J. Neurochem 1979; 32: 1331–1333.
  26. Freeman J.J., Jenden D.J. The source of choline for Ach synthesis in brain. Life Science 1976; 19: 949–962.
  27. Heiss W.-D. Detection of the penumbra as a rationale for therapy of ischemic stroke. Журн. неврол. и психиат. (Прилож. «Инсульт»). 2003; 9: 13–15.
  28. Jope R.S. Effects of phosphatidylcholine administration to rats on choline in blood and choline and Ach in brain. J. PET 1982; 220: 322–328.
  29. Jope R.S., Jenden D.J. Choline and phospholipid metabolism and synthesis of Ach in rat brain. J. Neuroscience Res. 1979; 4: 69–82.
  30. Loffelholtz K. Receptor regulation of choline phospholipid hydrolysis. Biochemical Pharmacol. 1989; 38: 1543–1544.
  31. Sandage Jr. et al. Reduction of infarct volume using citicoline. United States Patient 1999; 5: 872.
  32. Schehr R.S. New treatments for acute stroke. Nature Biotechnol. 1996; 14: 1549–1554.
  33. Schmidt D.E., Wecker L. CNS effects of choline administration : evidence for temporal dependence. Neuropharmacol. 1981; 20: 535–539.
  34. Secades J.J., Frontera G. CDP-choline: Pharmacological and clinical review. Methods Find Exp. Clin. Pharmacol. 1995; 17; Suppl. B.: 2–54.
  35. Studies on the pharmacological and biochemical effects of alfaglycerylphosphorylcholine in experimental animals. Report from Shionogy Research Laboratories.
  36. Tommasina C., Manzino M., Novello P., Pastorino P. Studio clinico dell’efficacia terapeutica e della tollerabilitа della colina alfoscerato in 15 soggetti con compromissione delle funzioni cognitive successiva ad ischemia cerebrale focale acuta. Rivista di Neuropsichiatria e Scienze Affini. 1991; 37: 21–28.
  37. Wurtmann R.J., Heftl F., Melamed E. Precursor control of neurotransmitter synthesis. Pharmacological Rev. 1981; 32: 331–335.
  38. Warach S., Pettigrew L.C., Dashe J.F. et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann. Neurol. 2000; 48: 5: 713–722.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Odinak M.M., Voznyuk I.A., Piradov M.A., Rumyantseva S.A., Kuznetsov A.N., Yanishevskiy S.N., Golokhvastov S.Y., Tsygan N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies